Synthesis and In-vivo Anticancer Evaluation of N-(4-oxo-2- (4-((5-aryl-1,3,4 thiadiazole-2yl) amino) Phenyl thiazolidine-3-yl) Benzamide derivative

The development of novel antitumor agents is paramount in the fight against drug resistance and its associated cardiotoxicity. The present study carried out a thorough anticancer evaluation of N- (4-oxo-2-(4-((5-aryl-1,3,4 thiadiazole-2yl) amino) phenyl thiazolidine-3-yl) benzamide (TH08) in Ehrlich ascites carcinoma (EAC) in Swiss albino mice. Our assessment included the measurement of tumor weight, the duration of survival for mice with tumors, and tumor cell growth inhibition. Additionally, we analyzed hematological parameters, like white and red blood cells and hemoglobin levels. The results we obtained clearly demonstrate that TH08 is a potent anticancer agent that exerts a positive effect on EAC cells. To determine TH08's effectiveness, We compared our findings to those achieved by using the standard medication, bleomycin. Our findings provide compelling evidence that TH08 has significant potential as a novel antitumor agent.